Minnesota's Solventum sells purification business to Thermo Fisher for $4.1 billion
M health care spinoff Solventum is selling its purification business to Thermo Fisher Scientific for $4.1 billion in cash to pay down its billions in outstanding debt. Solventum CEO Bryan Hanson said in a news release that the sale,
Trian Comments on Solventum’s Sale of its Purification & Filtration Business
Thermo Fisher’s release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business’ current profit as part of Solventum, with much of that improvement driven by lower allocated costs.
Activist investor Trian Fund Management plans to push Solventum to separate more of its businesses after the company’s $4.1 ...
Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...
Trian Fund Management, which beneficially owns about 5% of Solventum (SOLV) and is the company’s largest active shareholder, commented on ...
Solventum Corp. closed 20.58% short of its 52-week high of $96.05, which the company achieved on March 26th.
Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...
Healthcare solutions provider Solventum (NYSE:SOLV) will be reporting results tomorrow afternoon. Here’s what to look for.
BofA raised the firm’s price target on Solventum (SOLV) to $85 from $80 and keeps a Neutral rating on the shares after the company agreed to ...
Private Advisor Group LLC raised its position in Solventum Co. (NYSE:SOLV – Free Report) by 73.9% during the fourth quarter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback